Clinical Trial Update: Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Zongertinib (BI 1810631) for advanced non-small cell lung cancer with HER2 mutations; currently active/not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Zongertinib (Zongertinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Lung Cancer, Non-squamous, Non-small Cell | Phase 3 | Status: ACTIVE_NOT_RECRUITING